Donald Hurley, DO
Family Medicine · Charleston, SCNPI 1043206410
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,423 of the $18,070 with a category attached, or 79.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $4,198 and has fallen 56.1% since, to $1,844 in 2025. Among family medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 617 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2K
- Biogen$2K
- Pfizer$1K
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$1K
- plus $9K from 54 others
Across 256 payments — averaging $7379.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$686K
- Vertex$345K
- Pfizer$260K
- AstraZeneca$129K
- Seqirus USA Inc$119K
- Merck$85K
- plus $265K from 12 others
What the payments were for
- Speaking & faculty fees$9405%
- Travel & lodging$2,67815%
- Food & beverage$14,42380%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,070 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $92,750 |
| VascepaIcosapent Ethyl | 64 | $42,483 |
| FarxigaDapagliflozin Propanediol | 43 | $41,486 |
| JardianceEmpagliflozin | 34 | $40,588 |
| TrulicityDulaglutide | 25 | $30,567 |
| EliquisApixaban | 21 | $26,080 |
| MounjaroTirzepatide | 23 | $24,472 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $20,197 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $15,663 |
| Emgality PenGalcanezumab-Gnlm | 13 | $8,822 |
| Icosapent Ethyl | 26 | $8,334 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $7,276 |
| DayvigoLemborexant | 11 | $3,732 |
| Rosuvastatin Calcium | 239 | $3,209 |
| Nebivolol Hcl | 43 | $1,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,231 | $92,75060 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,279 | $61,68367 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,095 | $55,03948 claims |
| Boehringer IngelheimJardiance | $241 | $40,58834 claims |
| PfizerEliquis | $1,412 | $26,08021 claims |
| GSKTrelegy Ellipta | $766 | $15,66317 claims |
| Eisai Inc.Dayvigo | $242 | $3,73211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Charleston
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Andrew MartinColumbia$205K
- Ada StewartColumbia$186K
- Jeffrey BroderNorth Augusta$140K
- Terry NagelColumbia$112K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
- Jennifer StolinSummerville$59K
- Nicholas PenningsNorth Myrtle Beach$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.